RxDoctor Payments Data

Andrew Burrell, DO

Family Medicine · Mesa, AZNPI 1558355990

Payments from drug & device makers

$6,300in general payments, 2019–2025

Across 368 payments — averaging $17.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • AstraZeneca$822
  • Boehringer Ingelheim$527
  • GSK$369
  • Amgen$303
  • Sanofi-aventis U.S. LLC$262
  • plus $3K from 48 others

What the payments were for

  • Food & beverage$6,281100%
  • Education$190%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,300 in reported general payments places this provider in the 90th percentile of 2,099 family medicine providers in Arizona.

See all family medicine providers in Arizona

Medicare billing

Part B allowed, 2024
$290,399
Medicare patients
415
Services billed
5,542

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide63$83,572
EliquisApixaban41$34,351
JardianceEmpagliflozin32$33,953
OzempicSemaglutide25$29,471
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog24$21,730
JanuviaSitagliptin Phosphate24$19,611
TrulicityDulaglutide16$18,905
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog22$17,135
Soliqua 100-33Insulin Glargine/Lixisenatide11$16,286
Janumet XrSitagliptin Phos/Metformin Hcl20$11,248
LinzessLinaclotide14$8,274
VyvanseLisdexamfetamine Dimesylate15$5,670
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog13$4,445
Levothyroxine Sodium405$3,936
Lantus SolostarInsulin Glargine,hum.Rec.Anlog26$3,250

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$217$102,47779 claims
PfizerEliquis$217$34,35141 claims
Boehringer IngelheimJardiance$527$33,95332 claims
MerckJanuvia, Janumet Xr$114$30,85944 claims
Novo NordiskOzempic$242$29,47125 claims
Sanofi-aventis U.S. LLCSoliqua 100-33$262$16,28611 claims
AbbVieLinzess, Synthroid$1,207$9,79637 claims
Takeda Pharmaceuticals U.S.A., Inc.Vyvanse$124$5,67015 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,099 family medicine providers in Arizona.

Other family medicine in Mesa

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →